A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms patients who rely on compounded versions of the drug.

The popular medications may still suffer from local shortages, but FDA is confident that the national supply will remain stable.

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug Wegovy and diabetes treatment Ozempic without a fight. An industry group has sued the U.

The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and projected demand in the country, the Danish pharmaceutical company said.

Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug is no longer on the FDA shortage list.

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.

Telehealth provider Hims & Hers said it will tell consumers they need to seek “alternative options on the commercial dosing,” but in earnings Monday still forecast higher revenue and profits in 2025.

Makers of copycat versions of Novo Nordisk's (NVO) popular weight-loss drug semaglutide, also known as Ozempic and Wegovy, are suing the FDA for removing the GLP-1 medication from its shortage list. The Outsourcing Facilities Association,